effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities

Objective: Hemocoagulase agkistrodon (HCA), a thrombin-like enzyme (TLE) from the venom of the Chinese moccasin snake ( Deinagkistrodon acutus ), has been used in clinical practice as a hemostatic compound. The aim of this study was to further investigate the pharmacological properties of HCA. Materials and methods: Sodium dodecyl sulfate or native polyacrylamide gel electrophoresis (SDS- or N-PAGE) as well as enzyme linked immunosorbent assays (ELISAs) were conducted to study the effects of HCA on the human plasma fibrinogen and prothrombin levels, as well as its in vitro interactions with some coagulation factors. In addition, the bleeding time effects of HCA in the mouse tail-bleeding model as well as its effects on the fibrinogen levels in rabbits were determined in vivo. Results: In vitro results revealed that HCA exerts its procoagulant activities by hydrolyzing fibrinogen into segments that are easier to be absorbed, reducing the risk of thrombus formation. Besides, HCA could significantly inhibit the activation of prothrombin at the concentration of 0.3 μ M. Unexpectedly, we also found that HCA was able to strongly bind to factor X/Xa (in a ratio of 1:1) and thus inhibit the acceleration of active factor X to tissue plasminogen activator-catalyzed plasminogen activation, demonstrating that it could be less likely to lead to thrombus formation. Finally, in vivo results indicated that HCA could significantly shorten the bleeding time in the mouse tail-bleeding model and had no effect on the fibrinogen levels in rabbits. Conclusion: In summary, HCA, a unique and new family member of TLEs, may become a new clinical drug for the prevention and treatment of hemorrhage due to its unique and complex interactions with the blood system. Clarification of these features will enable us to further understand the mechanism of action of HCA and then promote its further application in clinical practice as a therapeutic drug.

[1]  Ya-nan Chang,et al.  Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[2]  G. Neshich,et al.  Citrus bioflavonoid, hesperetin, as inhibitor of two thrombin‐like snake venom serine proteases isolated from Crotalus simus , 2018, Toxicon : official journal of the International Society on Toxinology.

[3]  P. Rojnuckarin,et al.  The structure-function relationship of thrombin-like enzymes from the green pit viper (Trimeresurus albolabris). , 2015, Toxicon : official journal of the International Society on Toxinology.

[4]  B. Lentz,et al.  Factor Xa dimerization competes with prothrombinase complex formation on platelet-like membrane surfaces. , 2015, The Biochemical journal.

[5]  Lilong Jiang,et al.  Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa. , 2014, Thrombosis research.

[6]  S. Goto,et al.  Antithrombotic Therapy for Prevention of Various Thrombotic Diseases , 2013 .

[7]  A. Mukherjee,et al.  Biochemical and pharmacological properties of a new thrombin-like serine protease (Russelobin) from the venom of Russell's Viper (Daboia russelii russelii) and assessment of its therapeutic potential. , 2013, Biochimica et biophysica acta.

[8]  Yun Zhang,et al.  Purification, characterization and gene cloning of Da-36, a novel serine protease from Deinagkistrodon acutus venom. , 2013, Toxicon : official journal of the International Society on Toxinology.

[9]  J. Weitz,et al.  Batroxobin Binds Fibrin with Higher Affinity and Promotes Clot Expansion to a Greater Extent than Thrombin* , 2013, The Journal of Biological Chemistry.

[10]  Xiao-hua Wang,et al.  Biochemical properties and comparative pharmacology of a coagulant from Deinagkistrodon acutus snake venom. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  Danilo L Menaldo,et al.  Biochemical characterization and comparative analysis of two distinct serine proteases from Bothrops pirajai snake venom. , 2012, Biochimie.

[12]  Yan Zhang,et al.  Anticoagulation factor I, a snaclec (snake C-type lectin) from Agkistrodon acutus venom binds to FIX as well as FX: Ca2+ induced binding data. , 2012, Toxicon : official journal of the International Society on Toxinology.

[13]  D. Martins‐de‐Souza,et al.  Functional and structural characterization of a new serine protease with thrombin-like activity TLBan from Bothrops andianus (Andean Lancehead) snake venom. , 2012, Toxicon : official journal of the International Society on Toxinology.

[14]  N. Konishi,et al.  Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding , 2010, Thrombosis and Haemostasis.

[15]  F. V. Winck,et al.  Isolation and characterization of a new serine protease with thrombin-like activity (TLBm) from the venom of the snake Bothrops marajoensis. , 2010, Toxicon : official journal of the International Society on Toxinology.

[16]  K. Talbot,et al.  Enhanced fibrinolysis by proteolysed coagulation factor Xa. , 2010, Biochimica et biophysica acta.

[17]  Yun Tang,et al.  A multicenter, phase III trial of hemocoagulase Agkistrodon: hemostasis, coagulation, and safety in patients undergoing abdominal surgery. , 2010, Chinese medical journal.

[18]  Guangmei Yan,et al.  Enzymatic activities and functional characterization of a novel recombinant snake venom proteinase from Agkistrodon acutus. , 2009, Biochimie.

[19]  D. Monroe,et al.  The coagulation cascade in cirrhosis. , 2009, Clinics in liver disease.

[20]  G. Yan,et al.  A novel fibrinolytic enzyme from Cordyceps militaris, a Chinese traditional medicinal mushroom , 2008 .

[21]  S. Lord,et al.  B:b interactions are essential for polymerization of variant fibrinogens with impaired holes ‘a’ 1 , 2007, Journal of thrombosis and haemostasis : JTH.

[22]  Zong-hai Huang,et al.  [Phase IIa clinical trail of hemocoagulase acutus for injection]. , 2007, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[23]  V. Williams,et al.  Practical applications of snake venom toxins in haemostasis. , 2005, Toxicon : official journal of the International Society on Toxinology.

[24]  F. Markland,et al.  Snake venom fibrin(ogen)olytic enzymes. , 2005, Toxicon : official journal of the International Society on Toxinology.

[25]  E. Mihályi.  Review of some unusual effects of calcium binding to fibrinogen. , 2004, Biophysical chemistry.

[26]  M. G. Albuquerque,et al.  Snake venom thrombin-like enzymes: from reptilase to now , 2004, Cellular and Molecular Life Sciences CMLS.

[27]  T. Ng,et al.  Antithrombotic and thrombolytic activities of Agkisacutacin, a snake venom proteinase, in experimental models. , 2000, General pharmacology.

[28]  A Wisner,et al.  Snake venom proteins acting on hemostasis. , 2000, Biochimie.

[29]  K. Titani,et al.  Snake venom proteases affecting hemostasis and thrombosis. , 2000, Biochimica et biophysica acta.

[30]  C. Esmon.  Regulation of blood coagulation. , 2000, Biochimica et biophysica acta.

[31]  Q. Q. Huang,et al.  Purification, characterization, crystallization and preliminary X-ray diffraction of acuthrombin-B, a thrombin-like enzyme from Agkistrodon acutus venom. , 1999, Acta crystallographica. Section D, Biological crystallography.

[32]  F. Markland.  Snake venoms and the hemostatic system. , 1998, Toxicon : official journal of the International Society on Toxinology.

[33]  M. Teng,et al.  Purification, characterization and conformational analysis of a haemorrhagin from the venom of Agkistrodon acutus. , 1997, Toxicon : official journal of the International Society on Toxinology.

[34]  N. Yanagisawa,et al.  Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats , 1996, Journal of Neuroimmunology.

[35]  T. Morita,et al.  Binding properties of the coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. , 1994, European journal of biochemistry.

[36]  D. Warrell,et al.  Action of snake venom components on the haemostatic system. , 1993, Blood reviews.

[37]  J. Weisel,et al.  The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots. , 1993, Journal of molecular biology.

[38]  M. Carr,et al.  Influence of Ca2+ on the structure of reptilase-derived and thrombin-derived fibrin gels. , 1986, The Biochemical journal.

[39]  K. Mann,et al.  The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. , 1983, The Journal of biological chemistry.

[40]  E. Hurwitt,et al.  A new surgical absorbable hemostatic agent. Experimental and clinical evaluation. , 1960, American journal of surgery.

[41]  P. Palatty,et al.  The medicinal use of venoms and toxins. , 2013, Journal of the Indian Medical Association.

[42]  S. Mackessy.  Thrombin-Like Enzymes in Snake Venoms , 2010 .

[43]  W. Bode,et al.  Coagulation factors and their inhibitors. , 1994, Current opinion in structural biology.

[44]  K. Fujikawa,et al.  The role of serine proteases in the blood coagulation cascade. , 1979, Advances in enzymology and related areas of molecular biology.

[45]  M. Blombäck,et al.  Coagulation studies on „Reptilase”, an extract of the venom from Bothrops jararaca , 1957, Thrombosis and Haemostasis.